報價延遲最少15分鐘:2025/01/12 06:00 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.616 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.23/-0.56
|
|
企業價值
204.05M
|
| 資產負債 |
|
每股賬面淨值
-2.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
147.75M
|
|
每股收益
1.54
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 06:00 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. |